The ERK pathway has been investigated widely as a key effector of SHP2 inhibition in studies (Chan and Feng, 2007; Huang et al., 2014; Prahallad et al., 2015; Chen et al., 2016; Fedele et al., 2018; Mainardi et al., 2018; Rehman et al., 2018; Wong et al., 2018; Ahmed et al., 2019; García-Aranda and Redondo, 2019; Lu et al., 2019; Zhao et al., 2019; Martínez-Jiménez et al., 2020; Quintana et al., 2020) and may not be affected by SHP2 inhibitors in cancer cells with KRAS or BRAF mutations (Chen et al., 2016; Mainardi et al., 2018). Here, KRAS is linked to cancer.